Main menu

RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection


Using Oxford Nanopore sequencing, Peddu and Hill et al. profiled full-length cell-free RNA from blood plasma and uncovered over 270,000 novel transcripts — far beyond the reach of short-read methods. Utilising machine learning models, the team classified early stage oesophageal cancer and precancer with 100% sensitivity and specificity, demonstrating the potential of nanopore sequencing as a non-invasive tool for early cancer detection and monitoring.

'Here we show that nanopore sequencing can be leveraged to comprehensively characterize the vast, unannotated cell-free RNA transcriptome across healthy, precancerous, and cancerous disease states'

Peddu and Hill et al. 2025

Sample type: cell-free RNA from blood plasma

Kit: Ligation Sequencing Kit, Native Barcoding Kit

Authors: Vikas Peddu, Alexander Hill, Sree Lakshmi Velandi Maroli, Connor Mattingly, Joshua M.V. Gardner, Karen H. Miga, Rebecca C. Fitzgerald, Daniel H. Kim

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Nanopore technology

Subscribe to Nanopore updates Resources and publications What is the Nanopore Community

About Oxford Nanopore

News Company timeline Sustainability Leadership team Media resources & contacts For investors For partners Working at Oxford Nanopore Current vacancies Commercial information BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag